Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.51 |
| ▸ | MME | P08473 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3344866 | 1.00 | ACE (0.51) | ACEMMEALDH1A1L3MBTL1NPC1 | |
| SCHEMBL4905957 | 0.92 | TSHR (0.44) | ACEMMEALDH1A1L3MBTL1NPC1 | |
| SCHEMBL4905986 | 0.92 | TSHR (0.44) | ACEMMEALDH1A1L3MBTL1NPC1 | |
| SCHEMBL7349910 | 0.89 | ACE (0.63) | ACEMMEALDH1A1L3MBTL1NPC1 | |
| SCHEMBL8432066 | 0.89 | ACE (0.63) | ACEMMEALDH1A1L3MBTL1NPC1 | |
| SCHEMBL10710311 | 0.85 | ACE (0.53) | ACEMMEALDH1A1L3MBTL1NPC1 | |
| SCHEMBL4900062 | 0.81 | MME (0.44) | ACEMMEALDH1A1TSHR | |
| SCHEMBL5226142 | 0.81 | KDM1A (0.40) | L3MBTL1KDM1AMAOBKMT2A | |
| SCHEMBL8428949 | 0.80 | ACE (0.44) | ACEMMEALDH1A1L3MBTL1NPC1 | |
| SCHEMBL7876213 | 0.79 | ACE (0.61) | ACEMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080311609-A1 | Novel Molecular Probes | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080311609-A1 | Novel Molecular Probes | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080311609-A1 | Novel Molecular Probes | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1831187-A1 | NOVEL MOLECULAR PROBES | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006065218-A1 | NOVEL MOLECULAR PROBES | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311609-A1 | Novel Molecular Probes | BACE1, BACE2, PSEN1 | ACE 1128/4885MME 312/4885ALDH1A1 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.